 Cystic Fibrosis Transmembrane Conductance Regulator
"Cystic Fibrosis Transmembrane Conductance Regulator" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A chloride channel that regulates secretion in many exocrine tissues. Abnormalities in the CFTR gene have been shown to cause cystic fibrosis. (Hum Genet 1994;93(4):364-8)
| Descriptor ID |
D019005
|
| MeSH Number(s) |
D12.776.157.530.100.304.500 D12.776.157.530.400.175.125 D12.776.157.530.450.074.500.500.500.500 D12.776.543.550.450.175.125 D12.776.543.585.100.304.500 D12.776.543.585.400.175.125 D12.776.543.585.450.074.500.500.500.500
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Cystic Fibrosis Transmembrane Conductance Regulator".
Below are MeSH descriptors whose meaning is more specific than "Cystic Fibrosis Transmembrane Conductance Regulator".
This graph shows the total number of publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in this website by year, and whether "Cystic Fibrosis Transmembrane Conductance Regulator" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 1 | 0 | 1 | | 2000 | 1 | 0 | 1 | | 2001 | 1 | 1 | 2 | | 2002 | 4 | 1 | 5 | | 2003 | 1 | 2 | 3 | | 2004 | 5 | 3 | 8 | | 2005 | 1 | 1 | 2 | | 2006 | 5 | 3 | 8 | | 2007 | 5 | 3 | 8 | | 2008 | 3 | 3 | 6 | | 2009 | 7 | 1 | 8 | | 2010 | 3 | 1 | 4 | | 2011 | 3 | 3 | 6 | | 2012 | 2 | 1 | 3 | | 2013 | 4 | 0 | 4 | | 2014 | 4 | 2 | 6 | | 2015 | 6 | 1 | 7 | | 2016 | 4 | 6 | 10 | | 2017 | 4 | 4 | 8 | | 2018 | 11 | 3 | 14 | | 2019 | 7 | 9 | 16 | | 2020 | 10 | 6 | 16 | | 2021 | 12 | 10 | 22 | | 2022 | 10 | 16 | 26 | | 2023 | 1 | 22 | 23 | | 2024 | 8 | 2 | 10 | | 2025 | 7 | 8 | 15 |
To return to the timeline, click here.
Below are the most recent publications written about "Cystic Fibrosis Transmembrane Conductance Regulator" by people in Profiles.
-
Pittman JE, Morgan S, McCreary M, Vu PT, Jorth P, Heltshe S, Hoffman LR, Kelly A, Sagel SD, Singh PK, Solomon GM, Rosenfeld M, Ratjen F. Clinical Effectiveness of Elexacaftor/Tezacaftor/Ivacaftor in 6- to 11-Year-Olds with Cystic Fibrosis: An Observational Study. Ann Am Thorac Soc. 2025 Nov; 22(11):1696-1708.
-
Apablaza T, Barros-Poblete M, Delpiano L, Villanueva S, Guequen A, Tapia-Balladares B, Haq I, Tribiños F, Hernández-Rivas S, Verdon B, Biggart MGS, Sánchez Y, Ward C, Baxter BD, Restrepo D, Cornejo I, Tarran R, Catalán MA, Gray MA, Flores CA. Succinate Chemosensing Induces Cystic Fibrosis Transmembrane Conductance Regulator-dependent Airway Clearance that Is Impaired in Cystic Fibrosis. Am J Respir Cell Mol Biol. 2025 Nov; 73(5):769-779.
-
Durieu I, Clements B, Fabrizzi B, Mall MA, McKone E, Ramsey B, Tullis E, Taylor-Cousar JL, van der Meer R, Bachman E, Chin A, Conner S, Jennings M, Weinstock T, Colombo C, Robinson P. Impact of Elexacaftor/Tezacaftor/Ivacaftor on Glucose Tolerance and Abnormal Glucose Metabolism: A Phase 3b, Open-Label Clinical Trial. Am J Respir Crit Care Med. 2025 Oct; 211(10):1926-1934.
-
Daines CL, Polineni D, Tullis E, Costa S, Linnemann RW, Mall MA, McKone EF, Quon BS, Ringshausen FC, Selvadurai H, Taylor-Cousar JL, Withers NJ, Sawicki GS, Lee T, Ahluwalia N, Morlando Geiger J, Jennings M, Tan YV, Waltz D, Ramsey B, Griese M. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Adults and Adolescents with Cystic Fibrosis and at Least One F508del Allele: A Phase 3 Open-Label Extension Study. Am J Respir Crit Care Med. 2025 10; 211(10):1901-1914.
-
Sun L, Walls SA, Dang H, Quinney NL, Sears PR, Sadritabrizi T, Hasegawa K, Okuda K, Asakura T, Chang X, Zheng M, Mikami Y, Dizmond FU, Danilova D, Zhou L, Deshmukh A, Cholon DM, Radicioni G, Rogers TD, Kissner WJ, Markovetz MR, Guhr Lee TN, Gutay MI, Esther CR, Chua M, Grubb BR, Ehre C, Kesimer M, Hill DB, Ostrowski LE, Button B, Gentzsch M, Robinson C, Olivier KN, Freeman AF, Randell SH, Vladar E, O'Neal WK, Boucher RC, Chen G. STAT3-Dependent Regulation of CFTR and Ciliogenesis Is Essential for Mucociliary Clearance and Innate Airway Defense in Hyper-IgE Syndrome. Am J Respir Crit Care Med. 2025 Oct; 211(10):1951-1969.
-
Wainwright C, McColley SA, McNally P, Powers M, Ratjen F, Rayment JH, Retsch-Bogart G, Roesch E, Ramsey B, McKone EF, Tullis E, Mall MA, Taylor-Cousar JL, Waltz D, Ahluwalia N, Chu C, Scirica CV, Davies JC. Long-Term Safety and Efficacy of Elexacaftor/Tezacaftor/Ivacaftor in Children =6 Years with Cystic Fibrosis and at Least One F508del Allele: A 192-Week, Phase 3, Open-Label Extension Study. Am J Respir Crit Care Med. 2025 Oct; 211(10):1915-1925.
-
Joseph RA, Haley RM, Padilla MS, Ricciardi AS, Yamagata HM, Mitchell MJ. Cas9 Protein Outperforms mRNA in Lipid Nanoparticle-Mediated CFTR Repair. Nano Lett. 2025 Oct 01; 25(39):14348-14355.
-
Scharf G, Davidson CR, Ustiyan V, Falkenberg LG, Adavalli A, Meeker JD, Morgan H, Ostmann AJ, Hudock KM, Brewington JJ, Clancy JP, Kramer EL. TGF-ß induces excessive pulmonary IL-6 secretion in cystic fibrosis via PI3K. Am J Physiol Lung Cell Mol Physiol. 2025 Oct 01; 329(4):L470-L479.
-
Gross JE, Jones MC, Buige A, Prevots DR, Kasperbauer S. Pulmonary nontuberculous mycobacterial infections among women with cystic fibrosis and non-cystic fibrosis bronchiectasis. Ther Adv Respir Dis. 2025 Jan-Dec; 19:17534666251323181.
-
Fireizen Y, Ahmed M, Vigers T, Akong K, Ryu J, Hahn A, Fanous H, Koumbourlis A, Tirakitsoontorn P, Arrieta A, Burgener EB, Koff J, Cogen JD, Bouzek DC, Hanley E, Keck A, Stout D, Bradley J, Sagel SD. Changing Epidemiology of Pediatric Pulmonary Exacerbations in Cystic Fibrosis. Pediatr Pulmonol. 2025 Mar; 60(3):e71019.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|